BCHE and early-onset autosomal dominant Alzheimer disease: Cholinesterase inhibitors designed for the management of Alzheimer’s disease stem from the cholinergic hypothesis, which is the leading theory proposed to explain the pathogenesis of Alzheimer’s disease [37].